Copy Link Print Information

AZD-8055

72 Cited Publications
Avis client

Based on 72 publication(s) in Google Scholar

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.60%
  • CAS No.: 1009298-09-2
  • Formule: C25H31N5O4
  • Masse moléculaire:465.54
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • AZD-8055 Chemical Structure
    AZD-8055 Chemical Structure
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
  • Experimental Validation Results for AZD-8055
CAS No.: 1009298-09-2
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of AZD-8055:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) AZD-8055

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

Voir tous les produits spécifiques à Isoform mTOR

More
Keywords
100 mg

Obtenir un devis En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • AZD-8055 Chemical Structure
    AZD-8055 Chemical Structure
    1/16
  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Heliyon. 2023 Mar 6;9(3):e14272. [Abstract]

    Customer Validation
     AZD8055 (100, 500, 1000 nM; 48h) significantly suppresses the expression of pAKT, p-S6K1 and p-mTOR in both the T24 and 5637 human bladder urothelial carcinoma cell lines, and the SCaBER and UM-UC-3 human bladder squamous cell carcinoma cell line.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ED-40415 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, RAD001, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     HUT-102 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, RAD001, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     MT-2 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, RAD001, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ATL-43T cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, RAD001, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 11;8(28):45793-45806. [Abstract]

    Customer Validation
     Cells are treated for 2 h with AZD8055 at the indicated concentrations (0, 50, 200 and 800 nM), and cell lysates are probed with phosphor- and total antibodies of mTOR signaling pathway. β-actin is used as loading control. Blot shown is representative of at least two independent experiments.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Feb 21;8(8):12775-12783. [Abstract]

    Customer Validation
     OSI-027, AZD-8055 and AZD-2014 almost completely block MHY1485-induced mTOR activation (p-mTOR/S6K1/Akt Ser473) in skin keratinocytes.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Jan 28;11(1):e0147682. [Abstract]

    Customer Validation
     CHP-212 and SK-N-AS cells are treated with indicated concentrations of AZD6244, MEK162, RAD001 or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 are detected by specific anti-phospho antibodies. Loading is verified by specific antibodies to total AKT, ERK and anti-tubulin.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Sci Bull. 2015 Dec;60(24):2120-2128.

    Customer Validation
     CNE-2Z cells were treated with AZD-8055 with or without 1 T SMF for 3 d before they were harvested for Western blot.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Dec 8;6(39):42183-96. [Abstract]

    Customer Validation
     KNS-62 and T24 cells are treated with 250 nM AZD6244, 250 nM MEK162, 5 nM of RAD001, 250 nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot.

  • 1/16

    AZD-8055 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Apr 15;73(8):2574-86. [Abstract]

    Customer Validation
     Cells are treated with the indicated concentrations of AZD8055, Torin2 or staurosporin overnight and analyzed by western blot using antibodies specific for the indicated proteins.

  • AZD-8055